The Substance Abuse and Mental Health Services Administration (SAMHSA) has established a new policy prohibiting the use of federal grants for the distribution of drug test strips to the public. In a letter sent to local health departments and nonprofits, the Trump administration stated that these harm reduction practices are incompatible with federal laws and may facilitate illicit drug use.
This policy change follows a period of approximately 10 years during which test strips have been used to identify adulterants in street drugs. The decision affects various harm reduction strategies, including programs that provide clean needles, glass pipes, or specialized hotlines for people using drugs. Emily Hilliard, a spokesperson for the Department of Health and Human Services (HHS), stated that the administration intends to redirect federal funding toward "common-sense solutions" like naloxone, an overdose reversal nasal spray.
The restriction specifically targets public distribution but includes an exception for law enforcement, public health officials, and medical professionals. Organizations like the Baltimore Harm Reduction Coalition, which developed specific strips to detect benzodiazepines after mass overdose incidents in 2025, will now need to secure non-federal funding to continue providing these tools to the public. Yngvild Olsen, a former SAMHSA official, noted that evidence suggests these strips can lead users to reduce their intake or take additional safety precautions.
The concrete change for health organizations involves a redirection of resources; for example, the Baltimore Harm Reduction Coalition reported it may have to cut hygiene and wound care kits to maintain its supply of test strips using private funds. This shift occurs as local officials credit harm reduction tools with a 40% decline in Baltimore’s overdose deaths since 2023. Advocates express concern that losing federal support for these tools could lead to an increase in accidental overdoses if users are unable to verify the contents of substances obtained from the street.
The policy sets a precedent for federal oversight of harm reduction, prioritizing recovery-oriented and reversal-based interventions over tools that facilitate safer use. While law enforcement and medical professionals retain access to federal funds for drug testing, the public-facing distribution model is now defunded at the federal level. Nonprofits are currently navigating the transition to alternative funding sources to avoid service interruptions. No specific deadline for the exhaustion of existing grant funds was reported, though the policy guidance was issued in late April.